Association between plasma phospholipid omega-3 polyunsaturated fatty acids and type 2 diabetes is sex dependent: The Hunter Community Study.


Journal

Clinical nutrition (Edinburgh, Scotland)
ISSN: 1532-1983
Titre abrégé: Clin Nutr
Pays: England
ID NLM: 8309603

Informations de publication

Date de publication:
04 2020
Historique:
received: 08 10 2018
revised: 20 02 2019
accepted: 08 04 2019
pubmed: 27 4 2019
medline: 19 8 2021
entrez: 27 4 2019
Statut: ppublish

Résumé

Chronic inflammation drives the development of insulin resistance and type 2 diabetes. Long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) eicosapentaenoic acid (EPA, c20:5n-3) and docosahexaenoic acid (DHA, c22:6n-3) may protect against type 2 diabetes development. The aim of this current study is to determine whether LCn-3PUFA status is associated with type 2 diabetes in the Hunter Community Study. Men and women aged 55-85 years were randomly selected from the electoral roll and invited to participate. Participants were included in the current study if they had plasma phospholipid fatty acid composition data available and diabetes status could be determined. LCn-3PUFA status was determined by fatty acid composition of plasma phospholipids (EPA + DHA, %,w/w). Diabetes was determined according to World Health Organisation criteria. Insulin was measured in n = 251 participants and HOMA-IR calculated. In total, n = 2092 (diabetes: n = 249) participants were included. After adjusting for confounders of diabetes, LCn-3PUFA status was inversely associated with diabetes in overweight/obese females (OR [95%CI]: 0.90 [0.80, 1.00], p = 0.045) but not males (p-interaction This study provides further evidence of a sex-dependent association between LCn-3PUFA and type 2 diabetes. Causal pathways between LCn-3PUFA and type 2 diabetes merits delineation.

Sections du résumé

BACKGROUND & AIMS
Chronic inflammation drives the development of insulin resistance and type 2 diabetes. Long-chain omega-3 polyunsaturated fatty acids (LCn-3PUFA) eicosapentaenoic acid (EPA, c20:5n-3) and docosahexaenoic acid (DHA, c22:6n-3) may protect against type 2 diabetes development. The aim of this current study is to determine whether LCn-3PUFA status is associated with type 2 diabetes in the Hunter Community Study.
METHODS
Men and women aged 55-85 years were randomly selected from the electoral roll and invited to participate. Participants were included in the current study if they had plasma phospholipid fatty acid composition data available and diabetes status could be determined. LCn-3PUFA status was determined by fatty acid composition of plasma phospholipids (EPA + DHA, %,w/w). Diabetes was determined according to World Health Organisation criteria. Insulin was measured in n = 251 participants and HOMA-IR calculated.
RESULTS
In total, n = 2092 (diabetes: n = 249) participants were included. After adjusting for confounders of diabetes, LCn-3PUFA status was inversely associated with diabetes in overweight/obese females (OR [95%CI]: 0.90 [0.80, 1.00], p = 0.045) but not males (p-interaction
CONCLUSIONS
This study provides further evidence of a sex-dependent association between LCn-3PUFA and type 2 diabetes. Causal pathways between LCn-3PUFA and type 2 diabetes merits delineation.

Identifiants

pubmed: 31023487
pii: S0261-5614(19)30162-1
doi: 10.1016/j.clnu.2019.04.007
pii:
doi:

Substances chimiques

Fatty Acids, Omega-3 0
Phospholipids 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1059-1066

Informations de copyright

Copyright © 2019 Elsevier Ltd and European Society for Clinical Nutrition and Metabolism. All rights reserved.

Auteurs

Kylie A Abbott (KA)

Nutraceuticals Research Program, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia.

Tracy L Burrows (TL)

School of Health Sciences, University of Newcastle, NSW, Australia.

Rohith N Thota (RN)

Nutraceuticals Research Program, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia; Riddet Institute, Massey University, Palmerston North, New Zealand.

Anu Alex (A)

Nutraceuticals Research Program, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia.

Shamasunder Acharya (S)

Department of Diabetes and Endocrinology, John Hunter Hospital, Hunter New England Local Health District, Newcastle, NSW, Australia; School of Medicine and Public Health, University of Newcastle, NSW, Australia.

John Attia (J)

School of Medicine and Public Health, University of Newcastle, NSW, Australia; Hunter Medical Research Institute, Newcastle, NSW, Australia.

Mark McEvoy (M)

School of Medicine and Public Health, University of Newcastle, NSW, Australia; Hunter Medical Research Institute, Newcastle, NSW, Australia.

Manohar L Garg (ML)

Nutraceuticals Research Program, School of Biomedical Sciences and Pharmacy, University of Newcastle, NSW, Australia. Electronic address: Manohar.Garg@newcastle.edu.au.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH